GLP‑1 questions, answered

A GLP-1 is a prescription medication that copies a natural gut hormone called glucagon-like peptide-1, which your body releases after you eat. That hormone does three things: it prompts your pancreas to release insulin, it slows how fast food leaves your stomach, and it signals your brain that you have had enough. The natural version breaks down within minutes; these drugs are engineered to last for days, so the signal stays switched on. They were developed for type 2 diabetes, and the appetite effect turned out to produce weight loss large enough to become a treatment in its own right.

They work by making you eat less without having to force it. Food sits in your stomach longer so you stay full, appetite signaling in the brain turns down so you think about food less often (many people describe this as the "food noise" going quiet), and steadier blood sugar takes the edge off cravings. The weight comes off because you take in fewer calories, not because the drug burns fat directly. That is also why what you eat still matters: the medication decides how much you want, you still decide what it is.

The difference is how many gut-hormone receptors the drug switches on — "agonist" simply means a drug that activates a receptor. Semaglutide is a single agonist: it hits the GLP-1 receptor only. Tirzepatide is a dual agonist, hitting GLP-1 plus GIP (glucose-dependent insulinotropic polypeptide, a second gut hormone involved in insulin release and how the body handles fat). Retatrutide, still experimental, adds a third target, glucagon. So far, activating more receptors has produced more weight loss in trials — but more targets also means more ways to cause side effects, and the newest ones are the least studied.

Three are approved specifically for chronic weight management: Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide). The rest — Ozempic, Mounjaro, Rybelsus, Victoza, and Trulicity — are approved for type 2 diabetes, and several also carry heart or kidney indications. Ozempic and Mounjaro are frequently prescribed off-label for weight loss, which means legal but outside the approved use, and almost never covered by insurance in that situation. Approvals keep expanding, so the label a drug carried last year may not be the one it carries now.

No. Insulin is a hormone you inject to replace what your body cannot make or use properly; a GLP-1 is a drug that prompts your own pancreas to release insulin, and only when your blood sugar is actually elevated. That difference matters: on its own, a GLP-1 rarely causes low blood sugar, while insulin readily can. The confusion is understandable — both are injections, both are used in diabetes, both come in pen devices. If you already take insulin or a sulfonylurea, adding a GLP-1 does raise the risk of low blood sugar, so those doses usually need adjusting.

No — Wegovy, Zepbound, and Saxenda are approved for weight management in people who do not have diabetes. Qualification is based on BMI plus, in the lower BMI tier, a weight-related health condition such as high blood pressure or sleep apnea. Having type 2 diabetes changes which product is the natural fit and makes insurance coverage far more likely, but it is not a requirement. A licensed clinician still has to prescribe, because the safety screening applies either way.

There is one oral GLP-1 on the US market — Rybelsus, which is semaglutide in tablet form, approved for type 2 diabetes. It has to be taken on an empty stomach with no more than a small sip of water, and nothing else for the next 30 minutes, because the drug absorbs poorly otherwise. An oral semaglutide dose for weight management has been studied and is the most likely next pill to reach patients. Everything else in the class is an injection: a very short, thin needle into the fat just under the skin, most of them once a week.

The molecule is the active drug — semaglutide, tirzepatide, liraglutide. The brand is a specific FDA-approved product built on that molecule, with its own dose range, device, and approved use: semaglutide is sold as Ozempic, Wegovy, and Rybelsus, and they are not interchangeable despite sharing a molecule. A compounded version is that same molecule mixed by a compounding pharmacy rather than the manufacturer; it is not FDA-approved and has not been reviewed for safety, effectiveness, or quality. When a website advertises "semaglutide" at a low monthly price without naming a brand, it is almost always compounded.

In the pivotal trials, average total body-weight loss ran from roughly 8% on liraglutide to about 15% on semaglutide 2.4 mg and about 21% on the highest tirzepatide dose, over 68 to 72 weeks alongside diet and activity changes. For someone starting at 220 lb, that middle figure is around 33 lb. Those are averages, and the spread around them is wide — a meaningful minority lost far more, and some lost very little. Real-world results tend to come in lower than trial results, mostly because people interrupt doses, stop early, or never reach the full dose.

Appetite usually changes within the first few weeks, but the scale moves slowly at first by design. Every GLP-1 starts at a deliberately low dose that is not expected to do much, and steps up every four weeks or so, which means it takes roughly four to five months to reach a full maintenance dose. In the trials, weight loss kept accumulating for well over a year before flattening out. Judging the medication by month one is judging it during the warm-up.

Many people notice it within the first few days after the first injection — meals feel smaller, and food takes up less mental space. For others, nothing much happens until the second or third dose step, which is normal, because the starting dose exists to let your gut adapt rather than to work. The effect can also feel uneven: strongest in the day or two after an injection, lighter toward the end of the week. If you reach a full maintenance dose and still feel no change in appetite at all, that is worth raising with your prescriber rather than waiting it out.

Plateaus are normal and usually have a findable cause. The common ones: you are sitting between dose steps, your body now burns fewer calories at a lower weight, the appetite effect has softened as you adapted, intake has quietly crept back up, or you have reached what your current dose can do. Water shifts also mask real progress for a week or two at a time, so a flat scale is not automatically a flat trend. The things that actually restart it are unglamorous — verify what you are eating for a week, get protein and resistance training in place, and talk to your prescriber about the next dose step.

You will still lose weight, but you will get less out of the medication and give up more muscle doing it. The drug reduces how much you eat whether or not you plan anything, so calories fall by default. What it does not do is choose what you eat — and if the smaller amount you do eat is low in protein, more of the weight you lose comes off as lean tissue rather than fat. Every trial paired the drug with a reduced-calorie diet and activity, so the headline numbers describe medication plus effort, not medication alone.

On average, women in the trials lost a somewhat larger percentage of their body weight than men, while men often shed more total pounds early because they tend to start heavier. The gap is modest next to the person-to-person variation, so it is not a useful basis for choosing a medication or predicting your own result. Body composition differs too: men typically carry more muscle to begin with, which makes protein intake and resistance training matter for both groups but for slightly different reasons. Treat sex as one small factor among many, not a forecast.

A minority of people lose very little even at a full dose — trials often flag anything under about 5% of body weight by a set checkpoint as an inadequate response. Before concluding the drug failed, rule out the ordinary explanations: doses missed or interrupted, never actually reaching the maintenance dose, storage problems that degraded the pen, or another medication that drives weight gain. If everything checks out, switching molecules is the usual next move, and plenty of people who respond poorly to semaglutide do well on tirzepatide. That is a conversation with your prescriber, not a self-directed swap.

Full list prices for the branded weight-loss medications run roughly $1,000 to $1,400 a month, but very few people pay that. Manufacturer cash-pay programs sell some products direct at a substantially lower monthly price, savings cards cut the cost further for people with commercial insurance, and compounded versions through telehealth sit lower still. What you actually pay depends far more on which route you use than on which medication you choose. Check the current price on the manufacturer's own page before believing any figure you read anywhere, including here.

The list price is a starting point in a negotiation you are not part of. Manufacturers set it high, then hand back rebates to insurers and pharmacy benefit managers, so the price a plan pays is confidential and much lower — and the list price mainly ends up mattering to uninsured people and to anyone whose deductible has not been met. In response, manufacturers now run direct cash-pay channels that bypass the whole arrangement at a published price. That is why two people on the identical medication can pay wildly different amounts in the same month.

Sometimes, and far less often than for diabetes. Coverage for a diabetes indication is common; coverage for weight management depends entirely on your specific plan, and many employer plans exclude weight-loss medication outright as a category. Where it is covered, expect prior authorization, documented BMI and comorbidities, sometimes documented prior weight-loss attempts, and often step therapy requiring a cheaper drug first. Your plan documents or a call to the number on your card will answer this faster than any general article — ask specifically whether GLP-1s are covered for weight management, not just whether they are on the formulary.

Medicare has historically been barred from covering medications prescribed purely for weight loss, which is why coverage usually hinges on a different approved use — type 2 diabetes, or a cardiovascular or sleep-apnea indication that a given product carries. Medicaid varies state by state, with some states covering anti-obesity medications and others not covering them at all. This is one of the fastest-moving areas in GLP-1 policy, so the answer that was true last year may not be true today. Check current rules for your specific plan rather than relying on any general summary.

A savings card is a manufacturer coupon that reduces your copay at the pharmacy, and eligibility usually depends on having commercial insurance rather than a government plan. If your commercial plan covers the medication, the card can bring the monthly cost down sharply; if your plan does not cover it, a different tier of the same program may offer a reduced cash price instead. People on Medicare, Medicaid, or other federal programs are generally excluded by law from manufacturer copay assistance. Terms, caps, and duration change regularly, so read the current offer on the manufacturer's site rather than a third-party summary.

In rough order: insurance that actually covers it, then the manufacturer's own cash-pay program, then a savings card if you have commercial coverage, then a telehealth membership. Older medications in the class are cheaper than the newest ones, and a generic exists for at least one of them, so if cost is the binding constraint that is a conversation worth having with your prescriber. Compounded versions are usually the lowest sticker price, and they are also the least regulated — a real trade-off rather than a free win. What is never worth it is buying unregulated "peptides" online, where you have no idea what is in the vial.

Programs advertising compounded semaglutide or tirzepatide typically bundle the medication, clinician access, and supplies into a single monthly fee that is a fraction of branded list price. Programs that prescribe branded medication usually charge a separate membership fee on top of whatever the pharmacy charges for the drug itself, so the all-in number is higher. Watch for the structure, not the headline: introductory pricing that jumps after month one, prices quoted at the lowest dose only, and multi-month prepayments are all common. Get the total for the first six months at the dose you will actually be on before you sign up.

No. Compounded semaglutide and tirzepatide are mixed by pharmacies rather than manufacturers, and the FDA has not evaluated them for safety, effectiveness, or quality. That is a different situation from a generic drug, which is approved and proven equivalent to the brand. The practical risks are potency that varies between batches, added ingredients that were never studied in these products, and dosing errors — many compounded products come as a vial and syringe, where you measure the dose yourself in units. If you use one, it should come from a state-licensed pharmacy through a real prescriber, with instructions you follow exactly.

The rules tightened significantly once the FDA declared the branded shortages resolved. During a shortage, pharmacies are permitted to compound copies of an approved drug; once it ends, that permission narrows to genuinely individualized preparations for a specific patient need — not mass-produced copies. Providers still selling compounded GLP-1s generally argue their product is personalized in some way, such as a different concentration or an added ingredient. This is an actively contested legal area with ongoing litigation, so treat any confident claim in either direction, including one from a seller, with skepticism and check the current FDA position.

A 503A is a traditional compounding pharmacy that prepares medications for individual patients against individual prescriptions, and it is regulated primarily by its state board. A 503B is a registered outsourcing facility that produces larger batches, is inspected by the FDA, and must follow manufacturing quality standards that 503A pharmacies do not. Neither one makes an FDA-approved product, but a 503B carries more oversight of how the product is made. If a telehealth provider will not tell you which type of pharmacy fills its prescriptions, that itself is an answer.

Do not inject them. Products labeled "for research use only" or "not for human consumption" are sold under that language precisely so the seller avoids drug regulation — there is no oversight of what is in the vial, no verified potency, no sterility guarantee, and no accountability if something goes wrong. Independent testing of this market has repeatedly turned up wrong doses, wrong substances, and contamination. This is a different category from compounded medication dispensed by a licensed pharmacy against a prescription, even though the marketing often blurs the two deliberately.

A legitimate provider names its pharmacy, tells you whether it is 503A or 503B, connects you to a clinician licensed in your state, and gives you a real way to reach that clinician after you have paid. It requires a genuine medical intake and is willing to turn you down. It also gives you written dosing instructions in milligrams as well as syringe units, and does not pressure you into six months prepaid at a discount. Red flags run the other way: no named pharmacy, no clinician contact, "no prescription needed," prices that only exist if you buy a long block up front, and marketing that leans on urgency.

Not legally in the US — every GLP-1, branded or compounded, requires a prescription from a licensed clinician. Sites that ship without one are selling unregulated product, often from overseas, and counterfeit GLP-1 pens have been found in circulation with the wrong contents or no active drug at all. Beyond the obvious risk of injecting something unknown, you also lose the part that makes this treatment work: someone checking your history for contraindications, titrating your dose, and catching a serious side effect early. The prescription requirement is not the obstacle to getting treated; it is the treatment.

Into the fat just under the skin of your abdomen (staying a couple of inches away from your navel), the front of your thigh, or the back of your upper arm. Most people describe it as a pinch or nothing at all — the needles are very short and very thin, and the injection goes into fat rather than muscle. Rotate the site each week so the same patch of tissue does not thicken or dimple over time, and let the pen come to room temperature first, since cold liquid stings more. A little redness or itching at the site is common and usually settles within a day.

For weekly injections, any time of day works — the drug stays in your system all week, so consistency of day matters more than hour. Pick a day that suits your schedule rather than your metabolism: many people choose one that puts the roughest 24 to 48 hours on a quieter day. You can take it with or without food. Daily products are different — Saxenda and Victoza are taken at roughly the same time each day, and Rybelsus has to be first thing in the morning on an empty stomach.

Take it as soon as you remember if you are still within the window your medication's label allows, then continue on your usual schedule; if you are past that window, skip it and take the next dose on its normal day. Never double up to catch up — that increases side effects without improving results. The windows differ by product, so check your medication guide rather than assuming, and if you have missed several weeks in a row, contact your prescriber, because you will usually need to restart at a lower dose and step back up. Missing an occasional dose is common and not a setback worth panicking over.

Unopened pens are stored in the refrigerator, not the freezer, and never used if they have been frozen. Once in use, most pens can sit at room temperature for a limited number of days, which is what makes travel workable — check your specific medication guide for the number, because it varies by product. For flights, keep the pen in your carry-on, since checked baggage can freeze, and carry a small insulated bag with a cool pack that does not touch the pen directly. Keep it in its original box with the pharmacy label, and take a copy of your prescription if you are crossing borders; needles and pens are permitted through airport security.

Nothing is strictly forbidden, but a few categories reliably make people feel worse: fried and heavily fatty food, very large portions, carbonated drinks, and alcohol. Those all sit poorly in a stomach that is emptying slowly, and they are the usual culprits behind nausea, reflux, and sulfur burps. Very sugary foods can also cause an uncomfortable rush-and-crash for some people. The more useful frame is what to prioritize rather than avoid — protein first, then vegetables and fiber, then whatever else fits — because with a suppressed appetite you only get a few hundred calories to work with per meal.

Most guidance lands in the range of roughly 80 to 120 grams a day during active weight loss, scaled to your body size rather than applied as a flat number. The reasoning is that protein is the main lever protecting muscle while you are in a calorie deficit, and a suppressed appetite makes it very easy to fall short without noticing. In practice the hard part is not the target but the volume of food — front-loading protein at breakfast and using shakes or Greek yogurt to fill gaps is how most people get there. The underlying research largely comes from studies that did not involve GLP-1 users, so treat the numbers as a sensible aim rather than a proven prescription.